Orforglipron (Foundayo): The GLP-1 Pill, Explained

Orforglipron is a once-daily weight-loss pill from Eli Lilly. The FDA approved it on April 1, 2026 under the brand name Foundayo, for adults with obesity or with overweight plus a weight-related medical problem, used alongside a reduced-calorie diet and more physical activity [1].

It is the second GLP-1 pill approved for weight management in the US and the first that is a small molecule rather than a peptide. That distinction sounds technical, but it is the whole reason the drug exists, and it changes how you take it.

This article covers what it is, what the trials found, what it costs, and how it compares with the other options. It is not medical advice, and nothing here tells you whether this drug is right for you.

What is orforglipron and how is it different?

GLP-1 is a hormone your gut releases after you eat. It tells your pancreas to release insulin, slows how quickly your stomach empties, and signals fullness to your brain. Drugs in this class copy that signal.

Almost all of them are peptides, which are small proteins. Peptides get destroyed by stomach acid and digestive enzymes, which is why semaglutide, tirzepatide and liraglutide are injections. Novo Nordisk solved this for oral semaglutide by adding an absorption enhancer and requiring people to take it fasting, with no more than 4 ounces of water, and then wait at least 30 minutes before eating or drinking [12].

Orforglipron is not a peptide. It is a conventional small-molecule drug, the kind of thing chemists have been making into pills for a century. It survives digestion on its own. The label states it can be taken once daily, at any time of day, with or without food, and that tablets should be swallowed whole without breaking, crushing or chewing [1][13].

That makes it, in Lilly’s phrasing, the only GLP-1 pill for weight loss with no time, food or water restrictions [1][13].

Small molecules are also easier and cheaper to manufacture at scale than peptides, which matters for supply and eventually for price.

How much weight did people lose in the trials?

The pivotal study was ATTAIN-1, a Phase 3 trial in 3,127 adults with obesity or overweight with comorbidities, but without diabetes. Results were published in the New England Journal of Medicine [2].

At 72 weeks, on the highest dose:

• 12.4% mean weight loss (27.3 lbs) among participants who stayed on treatment, versus 0.9% on placebo [1][2].
• 11.1% mean weight loss (25 lbs) across all participants regardless of whether they completed, versus 2.1% on placebo [1].
• 59.6% lost at least 10% of body weight; 39.6% lost at least 15%; 20.1% lost at least 20% [2].
• Waist circumference fell by an average of 4.4 inches on the highest dose [2].

Those two different percentages for the same trial are not a mistake. Companies report an “efficacy estimand,” which estimates what would have happened if everyone had stayed on the drug, and a “treatment-regimen estimand,” which counts everyone including people who stopped. The first is always the larger number. Both are legitimate; they answer different questions.

A companion trial, ATTAIN-2, studied adults with obesity and type 2 diabetes and reported around 10.5% weight loss with HbA1c reductions of 1.3 to 1.8 percentage points. The ACHIEVE program studied orforglipron in type 2 diabetes specifically.

A separate Phase 3b trial, ATTAIN-MAINTAIN, asked a question many people actually have: can you come off the injection and hold your weight with a pill? Participants who had already lost weight on Wegovy or Zepbound in an earlier trial were switched to orforglipron or placebo. Over 52 weeks, those who switched to orforglipron from Wegovy held all but about 0.9 kg of their earlier loss, and those switching from Zepbound held all but about 5.0 kg, while the placebo groups regained substantially [8][9].

How does Foundayo compare with the Wegovy pill?

This is the comparison most people are actually making, since both are once-daily pills approved for the same purpose within four months of each other.

	Foundayo (orforglipron)	Wegovy pill (oral semaglutide 25 mg)
Maker	Eli Lilly	Novo Nordisk
Type	Small molecule	Peptide
Approved	April 1, 2026	December 22, 2025
How taken	Any time of day, with or without food	Fasting, with a small sip of water, wait before eating
Trial weight loss	12.4% at 72 weeks (efficacy estimand)	16.6% in participants who adhered; 13.6% at 64 weeks overall
Other approved uses	Chronic weight management	Chronic weight management plus reducing the risk of major adverse cardiovascular events
Self-pay starting price	$149/month (0.8 mg)	$149/month (1.5 mg)
Self-pay maintenance price	$299-$349/month	$299/month (25 mg)

Sources: [1][2][11][12][6][17][18]

Two honest caveats. First, those weight-loss numbers come from different trials in different populations and cannot be treated as a head-to-head result. Second, the Wegovy pill carries an indication for reducing cardiovascular risk that Foundayo does not, which may matter a great deal for some people and not at all for others.

On convenience, Foundayo has the clearer advantage. On market traction, Novo Nordisk is well ahead: by September 2026 the Wegovy pill was running about 183,000 US prescriptions a week to Foundayo’s 47,500 [10]. That gap reflects a three-month head start, an established brand and earlier insurance coverage rather than any clinical verdict [10][15].

How does a pill compare with the injections?

Injectable tirzepatide (Zepbound) has produced roughly 22.5% mean weight loss in its obesity trials, and injectable semaglutide around 17%, rising to 20.7% with the newer 7.2 mg Wegovy HD dose [16]. Orforglipron’s 12.4% is lower.

So the trade-off is fairly clear: pills are more convenient, injections have produced larger average weight loss in trials to date. For some people the pill’s convenience is what makes treatment sustainable at all, and a drug you actually keep taking beats one you abandon. For others, maximum weight loss is the point.

There is no single right answer, and this is exactly the kind of decision that belongs in a conversation with a healthcare provider who knows your medical history, your insurance, and what you have already tried.

What does Foundayo cost?

Lilly launched the drug through LillyDirect, its direct-to-patient platform, with free home delivery [1].

Regular self-pay pricing by dose [6][7][17]:

• 0.8 mg (starting dose): $149 per month
• 2.5 mg: $199 per month
• 5.5 mg and 9 mg: $299 per month
• 14.5 mg and 17.2 mg: $349 per month, or $299 with timely refills through the Self Pay Journey Program, which requires refilling within 45 days

A temporary discount is running. Through December 31, 2026, Lilly has reduced the 2.5 mg dose to $149 per month and the 5.5 mg dose to $199 per month [17]. Those prices are scheduled to revert to $199 and $299 after that date.

The widely quoted “$149 a month” headline is the starting dose only. Most people who titrate up to a maintenance dose will be budgeting against the $299 to $349 band once the temporary discount ends.

With insurance. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card [1][6].

With Medicare. Eligible Medicare Part D beneficiaries may be able to get Foundayo for about $50 per month through the Medicare GLP-1 Bridge program, which went live July 1, 2026 and runs through December 31, 2027 [1][6].

Manufacturer programs change with little notice, and eligibility rules for savings cards typically exclude people with government insurance. Verify current pricing and eligibility directly with the manufacturer or your pharmacy before making any financial plan around it.

What are the side effects and warnings?

The Foundayo label lists as common side effects: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, feeling tired, belching, heartburn, gas and hair loss [3].

The label also carries a boxed-style warning that Foundayo may cause thyroid tumors, including thyroid cancer, and states it should not be used by people who have or have had medullary thyroid carcinoma, or who have Multiple Endocrine Neoplasia syndrome type 2 [3].

Other serious risks listed on the label include pancreatitis, severe stomach problems, dehydration leading to kidney problems, low blood sugar when used with insulin or a sulfonylurea, serious allergic reactions, vision changes in people with type 2 diabetes, gallbladder problems, and an increased chance of food or liquid getting into the lungs during procedures involving anesthesia or deep sedation [3].

Two practical items from the label worth flagging because people miss them:

• Birth control pills may not work as well while taking Foundayo. The label says a healthcare provider may recommend another form of birth control for 30 days after starting and for 30 days after each dose increase [3].
• Tell every provider before surgery or procedures with anesthesia, because of the aspiration risk [3].

Anyone experiencing side effects should report them to their provider and can report to the FDA at 1-800-FDA-1088 or fda.gov/medwatch [3].

How has the launch actually gone?

Slower than Lilly hoped. Foundayo’s second-quarter 2026 sales were $98 million worldwide, including $67 million in the US, below Wall Street consensus [15]. Weekly prescriptions hovered around 20,000 for much of May and June before climbing through the summer, crossing 40,000 in late August and reaching about 47,500 by mid-September [10].

Lilly has pointed to three factors: building awareness for a brand-new name takes time; insurance coverage from all three major pharmacy benefit managers was not in place until June; and a meaningful share of prescriptions run through telehealth channels that prescription-tracking data may under-count [10][15]. Lilly’s US president said in August 2026 that the company was “starting to see an inflection point” [10].

For a patient, none of this matters directly, except in one way: broader coverage generally makes a drug easier to get and cheaper to fill.

Questions worth asking a healthcare provider

If you are considering any GLP-1 medication, these are reasonable things to raise:

• Does my insurance cover this, and at what tier?
• Do I have a personal or family history of medullary thyroid cancer, MEN 2, pancreatitis, or gallbladder disease?
• Do I take insulin or a sulfonylurea, and does that change the plan?
• What should I do if nausea or constipation becomes hard to manage?
• If I use oral contraception, what should I do during dose increases?
• What happens if I stop? What does maintenance look like?

The label states how the medicine is used. Only a provider who knows your history can say whether it fits you.

Sources

1. Eli Lilly, “FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions” — https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
2. Eli Lilly, “Complete ATTAIN-1 results published in The New England Journal of Medicine” — https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight
3. Eli Lilly, Foundayo indication and safety summary with warnings (published with the July 2026 retatrutide release) — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
4. STAT News, “Eli Lilly’s obesity pill approved by FDA” — https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/
5. Associated Press, “FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity” — https://apnews.com/article/eli-lilly-orforglipron-glp1-weight-loss-obesity-ac23734a63e8354b5d9f0c93718ef2ff
6. Drugs.com, “How much does Foundayo cost?” — https://www.drugs.com/medical-answers/how-foundayo-cost-3582156/
7. Noom, “Foundayo (Orforglipron) Cost in 2026: With and Without Insurance” — https://www.noom.com/blog/weight-management/foundayo-cost-with-and-without-insurance/
8. Eli Lilly, “Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins” — https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after
9. Nature Medicine, “Orforglipron for maintenance of body weight reduction: the phase 3b ATTAIN-MAINTAIN trial” — https://www.nature.com/articles/s41591-026-04386-7
10. Fierce Pharma, “The Oral GLP-1 Tracker” — https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
11. Novo Nordisk, “FDA approves Novo Nordisk’s Wegovy pill” — https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
12. Medscape, “FDA Okays Oral Semaglutide 25 mg for Weight Management” — https://www.medscape.com/viewarticle/fda-okays-oral-semaglutide-25-mg-weight-management-2025a100104g
13. American Journal of Managed Care, “FDA Approves Lilly’s Oral GLP-1 Orforglipron for Obesity” — https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity
14. Eli Lilly, ATTAIN subgroup results in women across menopause stages — https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-only-oral-glp-1-taken-without-food
15. Fierce Pharma, “Lilly’s obesity pill Foundayo ‘disappointed’ in Q2” — https://www.fiercepharma.com/pharma/while-sales-lillys-obesity-pill-disappointed-q2-injectables-continue-boom
16. Ozmosi, “The Obesity Drug Pipeline in 2026” — https://www.ozmosi.com/obesity-drug-pipeline/
17. Eli Lilly, Foundayo coverage and savings (manufacturer self-pay price list) — https://foundayo.lilly.com/coverage-savings
18. NovoCare, Wegovy cost and coverage pricing table — https://www.novocare.com/patient/medicines/wegovy.html